Skip to main content
PMC home page
Thorax logoLink to Thorax
. 1998 Mar;53(3):213–219. doi: 10.1136/thx.53.3.213

Pseudomonas aeruginosa and other related species

R Wilson, R Dowling
PMCID: PMC1745165  PMID: 9659359

Full Text

The Full Text of this article is available as a PDF (132.0 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Abman S. H., Ogle J. W., Harbeck R. J., Butler-Simon N., Hammond K. B., Accurso F. J. Early bacteriologic, immunologic, and clinical courses of young infants with cystic fibrosis identified by neonatal screening. J Pediatr. 1991 Aug;119(2):211–217. doi: 10.1016/s0022-3476(05)80729-2. [DOI] [PubMed] [Google Scholar]
  2. Amitani R., Wilson R., Rutman A., Read R., Ward C., Burnett D., Stockley R. A., Cole P. J. Effects of human neutrophil elastase and Pseudomonas aeruginosa proteinases on human respiratory epithelium. Am J Respir Cell Mol Biol. 1991 Jan;4(1):26–32. doi: 10.1165/ajrcmb/4.1.26. [DOI] [PubMed] [Google Scholar]
  3. Anderson R. Erythromycin and roxithromycin potentiate human neutrophil locomotion in vitro by inhibition of leukoattractant-activated superoxide generation and autooxidation. J Infect Dis. 1989 May;159(5):966–973. doi: 10.1093/infdis/159.5.966. [DOI] [PubMed] [Google Scholar]
  4. App E. M., King M., Helfesrieder R., Köhler D., Matthys H. Acute and long-term amiloride inhalation in cystic fibrosis lung disease. A rational approach to cystic fibrosis therapy. Am Rev Respir Dis. 1990 Mar;141(3):605–612. doi: 10.1164/ajrccm/141.3.605. [DOI] [PubMed] [Google Scholar]
  5. Armstrong D. S., Grimwood K., Carzino R., Carlin J. B., Olinsky A., Phelan P. D. Lower respiratory infection and inflammation in infants with newly diagnosed cystic fibrosis. BMJ. 1995 Jun 17;310(6994):1571–1572. doi: 10.1136/bmj.310.6994.1571. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Auerbach H. S., Williams M., Kirkpatrick J. A., Colten H. R. Alternate-day prednisone reduces morbidity and improves pulmonary function in cystic fibrosis. Lancet. 1985 Sep 28;2(8457):686–688. doi: 10.1016/s0140-6736(85)92929-0. [DOI] [PubMed] [Google Scholar]
  7. Baker N. R., Minor V., Deal C., Shahrabadi M. S., Simpson D. A., Woods D. E. Pseudomonas aeruginosa exoenzyme S is an adhesion. Infect Immun. 1991 Sep;59(9):2859–2863. doi: 10.1128/iai.59.9.2859-2863.1991. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Baker N., Hansson G. C., Leffler H., Riise G., Svanborg-Edén C. Glycosphingolipid receptors for Pseudomonas aeruginosa. Infect Immun. 1990 Jul;58(7):2361–2366. doi: 10.1128/iai.58.7.2361-2366.1990. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Baldwin D. R., Honeybourne D., Wise R. Pulmonary disposition of antimicrobial agents: in vivo observations and clinical relevance. Antimicrob Agents Chemother. 1992 Jun;36(6):1176–1180. doi: 10.1128/aac.36.6.1176. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Baltimore R. S., Christie C. D., Smith G. J. Immunohistopathologic localization of Pseudomonas aeruginosa in lungs from patients with cystic fibrosis. Implications for the pathogenesis of progressive lung deterioration. Am Rev Respir Dis. 1989 Dec;140(6):1650–1661. doi: 10.1164/ajrccm/140.6.1650. [DOI] [PubMed] [Google Scholar]
  11. Beaudry P. H., Marks M. I., McDougall D., Desmond K., Rangel R. Is anti-Pseudomonas therapy warranted in acute respiratory exacerbations in children with cystic fibrosis? J Pediatr. 1980 Jul;97(1):144–147. doi: 10.1016/s0022-3476(80)80155-7. [DOI] [PubMed] [Google Scholar]
  12. Berger M., Sorensen R. U., Tosi M. F., Dearborn D. G., Döring G. Complement receptor expression on neutrophils at an inflammatory site, the Pseudomonas-infected lung in cystic fibrosis. J Clin Invest. 1989 Oct;84(4):1302–1313. doi: 10.1172/JCI114298. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Bruce M. C., Poncz L., Klinger J. D., Stern R. C., Tomashefski J. F., Jr, Dearborn D. G. Biochemical and pathologic evidence for proteolytic destruction of lung connective tissue in cystic fibrosis. Am Rev Respir Dis. 1985 Sep;132(3):529–535. doi: 10.1164/arrd.1985.132.3.529. [DOI] [PubMed] [Google Scholar]
  14. Buret A., Cripps A. W. The immunoevasive activities of Pseudomonas aeruginosa. Relevance for cystic fibrosis. Am Rev Respir Dis. 1993 Sep;148(3):793–805. doi: 10.1164/ajrccm/148.3.793. [DOI] [PubMed] [Google Scholar]
  15. Buret A., Ward K. H., Olson M. E., Costerton J. W. An in vivo model to study the pathobiology of infectious biofilms on biomaterial surfaces. J Biomed Mater Res. 1991 Jul;25(7):865–874. doi: 10.1002/jbm.820250706. [DOI] [PubMed] [Google Scholar]
  16. Carnoy C., Ramphal R., Scharfman A., Lo-Guidice J. M., Houdret N., Klein A., Galabert C., Lamblin G., Roussel P. Altered carbohydrate composition of salivary mucins from patients with cystic fibrosis and the adhesion of Pseudomonas aeruginosa. Am J Respir Cell Mol Biol. 1993 Sep;9(3):323–334. doi: 10.1165/ajrcmb/9.3.323. [DOI] [PubMed] [Google Scholar]
  17. Carswell F., Ward C., Cook D. A., Speller D. C. A controlled trial of nebulized aminoglycoside and oral flucloxacillin versus placebo in the outpatient management of children with cystic fibrosis. Br J Dis Chest. 1987 Oct;81(4):356–360. doi: 10.1016/0007-0971(87)90184-7. [DOI] [PubMed] [Google Scholar]
  18. Chen H. Y., Yuan M., Ibrahim-Elmagboul I. B., Livermore D. M. National survey of susceptibility to antimicrobials amongst clinical isolates of Pseudomonas aeruginosa. J Antimicrob Chemother. 1995 Apr;35(4):521–534. doi: 10.1093/jac/35.4.521. [DOI] [PubMed] [Google Scholar]
  19. Cheng K., Smyth R. L., Govan J. R., Doherty C., Winstanley C., Denning N., Heaf D. P., van Saene H., Hart C. A. Spread of beta-lactam-resistant Pseudomonas aeruginosa in a cystic fibrosis clinic. Lancet. 1996 Sep 7;348(9028):639–642. doi: 10.1016/S0140-6736(96)05169-0. [DOI] [PubMed] [Google Scholar]
  20. Cheng P. W., Boat T. F., Cranfill K., Yankaskas J. R., Boucher R. C. Increased sulfation of glycoconjugates by cultured nasal epithelial cells from patients with cystic fibrosis. J Clin Invest. 1989 Jul;84(1):68–72. doi: 10.1172/JCI114171. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Cryz S. J., Jr, Wedgwood J., Lang A. B., Ruedeberg A., Que J. U., Fürer E., Schaad U. B. Immunization of noncolonized cystic fibrosis patients against Pseudomonas aeruginosa. J Infect Dis. 1994 May;169(5):1159–1162. doi: 10.1093/infdis/169.5.1159. [DOI] [PubMed] [Google Scholar]
  22. Currie D. C., Pavia D., Agnew J. E., Lopez-Vidriero M. T., Diamond P. D., Cole P. J., Clarke S. W. Impaired tracheobronchial clearance in bronchiectasis. Thorax. 1987 Feb;42(2):126–130. doi: 10.1136/thx.42.2.126. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Currie D. C., Peters A. M., Garbett N. D., George P., Strickland B., Lavender J. P., Cole P. J. Indium-111 labelled granulocyte scanning to detect inflammation in the lungs of patients with chronic sputum expectoration. Thorax. 1990 Jul;45(7):541–544. doi: 10.1136/thx.45.7.541. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Eller J., Lapa e Silva J. R., Poulter L. W., Lode H., Cole P. J. Cells and cytokines in chronic bronchial infection. Ann N Y Acad Sci. 1994 May 28;725:331–345. doi: 10.1111/j.1749-6632.1994.tb39816.x. [DOI] [PubMed] [Google Scholar]
  25. Evans S. A., Turner S. M., Bosch B. J., Hardy C. C., Woodhead M. A. Lung function in bronchiectasis: the influence of Pseudomonas aeruginosa. Eur Respir J. 1996 Aug;9(8):1601–1604. doi: 10.1183/09031936.96.09081601. [DOI] [PubMed] [Google Scholar]
  26. Eyraud A., Descotes J., Lombard J. Y., Laschi-Loquerie A., Tachon P., Veysseyre C., Evreux J. C. Effects of erythromycin, josamycin and spiramycin on rat polymorphonuclear leukocyte chemotaxis. Chemotherapy. 1986;32(4):379–382. doi: 10.1159/000238438. [DOI] [PubMed] [Google Scholar]
  27. Feldman C., Anderson R., Kanthakumar K., Vargas A., Cole P. J., Wilson R. Oxidant-mediated ciliary dysfunction in human respiratory epithelium. Free Radic Biol Med. 1994 Jul;17(1):1–10. doi: 10.1016/0891-5849(94)90002-7. [DOI] [PubMed] [Google Scholar]
  28. Fick R. B., Jr Pathogenesis of the pseudomonas lung lesion in cystic fibrosis. Chest. 1989 Jul;96(1):158–164. doi: 10.1378/chest.96.1.158. [DOI] [PubMed] [Google Scholar]
  29. Gladman G., Connor P. J., Williams R. F., David T. J. Controlled study of Pseudomonas cepacia and Pseudomonas maltophilia in cystic fibrosis. Arch Dis Child. 1992 Feb;67(2):192–195. doi: 10.1136/adc.67.2.192. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Gold R., Carpenter S., Heurter H., Corey M., Levison H. Randomized trial of ceftazidime versus placebo in the management of acute respiratory exacerbations in patients with cystic fibrosis. J Pediatr. 1987 Dec;111(6 Pt 1):907–913. doi: 10.1016/s0022-3476(87)80217-2. [DOI] [PubMed] [Google Scholar]
  31. Goldman M. J., Anderson G. M., Stolzenberg E. D., Kari U. P., Zasloff M., Wilson J. M. Human beta-defensin-1 is a salt-sensitive antibiotic in lung that is inactivated in cystic fibrosis. Cell. 1997 Feb 21;88(4):553–560. doi: 10.1016/s0092-8674(00)81895-4. [DOI] [PubMed] [Google Scholar]
  32. Goswami S. K., Kivity S., Marom Z. Erythromycin inhibits respiratory glycoconjugate secretion from human airways in vitro. Am Rev Respir Dis. 1990 Jan;141(1):72–78. doi: 10.1164/ajrccm/141.1.72. [DOI] [PubMed] [Google Scholar]
  33. Govan J. R., Harris G. S. Pseudomonas aeruginosa and cystic fibrosis: unusual bacterial adaptation and pathogenesis. Microbiol Sci. 1986 Oct;3(10):302–308. [PubMed] [Google Scholar]
  34. Grimwood K., Semple R. A., Rabin H. R., Sokol P. A., Woods D. E. Elevated exoenzyme expression by Pseudomonas aeruginosa is correlated with exacerbations of lung disease in cystic fibrosis. Pediatr Pulmonol. 1993 Mar;15(3):135–139. doi: 10.1002/ppul.1950150302. [DOI] [PubMed] [Google Scholar]
  35. Grimwood K., To M., Rabin H. R., Woods D. E. Inhibition of Pseudomonas aeruginosa exoenzyme expression by subinhibitory antibiotic concentrations. Antimicrob Agents Chemother. 1989 Jan;33(1):41–47. doi: 10.1128/aac.33.1.41. [DOI] [PMC free article] [PubMed] [Google Scholar]
  36. Hodson M. E., Penketh A. R., Batten J. C. Aerosol carbenicillin and gentamicin treatment of Pseudomonas aeruginosa infection in patients with cystic fibrosis. Lancet. 1981 Nov 21;2(8256):1137–1139. doi: 10.1016/s0140-6736(81)90588-2. [DOI] [PubMed] [Google Scholar]
  37. Hoiby N. Pseudomonas aeruginosa infection in cystic fibrosis. Diagnostic and prognostic significance of pseudomonas aeruginosa precipitins determined by means of crossed immunoelectrophoresis. A survey. Acta Pathol Microbiol Scand Suppl. 1977;(262):1–96. [PubMed] [Google Scholar]
  38. Hubbard R. C., McElvaney N. G., Birrer P., Shak S., Robinson W. W., Jolley C., Wu M., Chernick M. S., Crystal R. G. A preliminary study of aerosolized recombinant human deoxyribonuclease I in the treatment of cystic fibrosis. N Engl J Med. 1992 Mar 19;326(12):812–815. doi: 10.1056/NEJM199203193261207. [DOI] [PubMed] [Google Scholar]
  39. Ichimiya T., Yamasaki T., Nasu M. In-vitro effects of antimicrobial agents on Pseudomonas aeruginosa biofilm formation. J Antimicrob Chemother. 1994 Sep;34(3):331–341. doi: 10.1093/jac/34.3.331. [DOI] [PubMed] [Google Scholar]
  40. Imundo L., Barasch J., Prince A., Al-Awqati Q. Cystic fibrosis epithelial cells have a receptor for pathogenic bacteria on their apical surface. Proc Natl Acad Sci U S A. 1995 Mar 28;92(7):3019–3023. doi: 10.1073/pnas.92.7.3019. [DOI] [PMC free article] [PubMed] [Google Scholar]
  41. Isles A., Maclusky I., Corey M., Gold R., Prober C., Fleming P., Levison H. Pseudomonas cepacia infection in cystic fibrosis: an emerging problem. J Pediatr. 1984 Feb;104(2):206–210. doi: 10.1016/s0022-3476(84)80993-2. [DOI] [PubMed] [Google Scholar]
  42. Jensen E. T., Kharazmi A., Lam K., Costerton J. W., Høiby N. Human polymorphonuclear leukocyte response to Pseudomonas aeruginosa grown in biofilms. Infect Immun. 1990 Jul;58(7):2383–2385. doi: 10.1128/iai.58.7.2383-2385.1990. [DOI] [PMC free article] [PubMed] [Google Scholar]
  43. Jensen T., Pedersen S. S., Garne S., Heilmann C., Høiby N., Koch C. Colistin inhalation therapy in cystic fibrosis patients with chronic Pseudomonas aeruginosa lung infection. J Antimicrob Chemother. 1987 Jun;19(6):831–838. doi: 10.1093/jac/19.6.831. [DOI] [PubMed] [Google Scholar]
  44. John M., Ecclestone E., Hunter E., Couroux P., Hussain Z. Epidemiology of Pseudomonas cepacia colonization among patients with cystic fibrosis. Pediatr Pulmonol. 1994 Aug;18(2):108–113. doi: 10.1002/ppul.1950180210. [DOI] [PubMed] [Google Scholar]
  45. Konstan M. W., Byard P. J., Hoppel C. L., Davis P. B. Effect of high-dose ibuprofen in patients with cystic fibrosis. N Engl J Med. 1995 Mar 30;332(13):848–854. doi: 10.1056/NEJM199503303321303. [DOI] [PubMed] [Google Scholar]
  46. Konstan M. W., Hilliard K. A., Norvell T. M., Berger M. Bronchoalveolar lavage findings in cystic fibrosis patients with stable, clinically mild lung disease suggest ongoing infection and inflammation. Am J Respir Crit Care Med. 1994 Aug;150(2):448–454. doi: 10.1164/ajrccm.150.2.8049828. [DOI] [PubMed] [Google Scholar]
  47. Krivan H. C., Roberts D. D., Ginsburg V. Many pulmonary pathogenic bacteria bind specifically to the carbohydrate sequence GalNAc beta 1-4Gal found in some glycolipids. Proc Natl Acad Sci U S A. 1988 Aug;85(16):6157–6161. doi: 10.1073/pnas.85.16.6157. [DOI] [PMC free article] [PubMed] [Google Scholar]
  48. Kronborg G., Hansen M. B., Svenson M., Fomsgaard A., Høiby N., Bendtzen K. Cytokines in sputum and serum from patients with cystic fibrosis and chronic Pseudomonas aeruginosa infection as markers of destructive inflammation in the lungs. Pediatr Pulmonol. 1993 May;15(5):292–297. doi: 10.1002/ppul.1950150506. [DOI] [PubMed] [Google Scholar]
  49. Kubesch P., Dörk T., Wulbrand U., Kälin N., Neumann T., Wulf B., Geerlings H., Weissbrodt H., von der Hardt H., Tümmler B. Genetic determinants of airways' colonisation with Pseudomonas aeruginosa in cystic fibrosis. Lancet. 1993 Jan 23;341(8839):189–193. doi: 10.1016/0140-6736(93)90062-l. [DOI] [PubMed] [Google Scholar]
  50. Leelarasamee A., Bovornkitti S. Melioidosis: review and update. Rev Infect Dis. 1989 May-Jun;11(3):413–425. doi: 10.1093/clinids/11.3.413. [DOI] [PubMed] [Google Scholar]
  51. Lethem M. I., James S. L., Marriott C., Burke J. F. The origin of DNA associated with mucus glycoproteins in cystic fibrosis sputum. Eur Respir J. 1990 Jan;3(1):19–23. [PubMed] [Google Scholar]
  52. LiPuma J. J., Dasen S. E., Nielson D. W., Stern R. C., Stull T. L. Person-to-person transmission of Pseudomonas cepacia between patients with cystic fibrosis. Lancet. 1990 Nov 3;336(8723):1094–1096. doi: 10.1016/0140-6736(90)92571-x. [DOI] [PubMed] [Google Scholar]
  53. Loutit J. S., Tompkins L. S. Restriction enzyme and Southern hybridization analyses of Pseudomonas aeruginosa strains from patients with cystic fibrosis. J Clin Microbiol. 1991 Dec;29(12):2897–2900. doi: 10.1128/jcm.29.12.2897-2900.1991. [DOI] [PMC free article] [PubMed] [Google Scholar]
  54. Massion P. P., Inoue H., Richman-Eisenstat J., Grunberger D., Jorens P. G., Housset B., Pittet J. F., Wiener-Kronish J. P., Nadel J. A. Novel Pseudomonas product stimulates interleukin-8 production in airway epithelial cells in vitro. J Clin Invest. 1994 Jan;93(1):26–32. doi: 10.1172/JCI116954. [DOI] [PMC free article] [PubMed] [Google Scholar]
  55. Matthews W. J., Jr, Williams M., Oliphint B., Geha R., Colten H. R. Hypogammaglobulinemia in patients with cystic fibrosis. N Engl J Med. 1980 Jan 31;302(5):245–249. doi: 10.1056/NEJM198001313020501. [DOI] [PubMed] [Google Scholar]
  56. McElvaney N. G., Hubbard R. C., Birrer P., Chernick M. S., Caplan D. B., Frank M. M., Crystal R. G. Aerosol alpha 1-antitrypsin treatment for cystic fibrosis. Lancet. 1991 Feb 16;337(8738):392–394. doi: 10.1016/0140-6736(91)91167-s. [DOI] [PubMed] [Google Scholar]
  57. McElvaney N. G., Nakamura H., Birrer P., Hébert C. A., Wong W. L., Alphonso M., Baker J. B., Catalano M. A., Crystal R. G. Modulation of airway inflammation in cystic fibrosis. In vivo suppression of interleukin-8 levels on the respiratory epithelial surface by aerosolization of recombinant secretory leukoprotease inhibitor. J Clin Invest. 1992 Oct;90(4):1296–1301. doi: 10.1172/JCI115994. [DOI] [PMC free article] [PubMed] [Google Scholar]
  58. Meyer K. C., Lewandoski J. R., Zimmerman J. J., Nunley D., Calhoun W. J., Dopico G. A. Human neutrophil elastase and elastase/alpha 1-antiprotease complex in cystic fibrosis. Comparison with interstitial lung disease and evaluation of the effect of intravenously administered antibiotic therapy. Am Rev Respir Dis. 1991 Sep;144(3 Pt 1):580–585. doi: 10.1164/ajrccm/144.3_Pt_1.580. [DOI] [PubMed] [Google Scholar]
  59. Morihara K., Tsuzuki H., Oda K. Protease and elastase of Pseudomonas aeruginosa: inactivation of human plasma alpha 1-proteinase inhibitor. Infect Immun. 1979 Apr;24(1):188–193. doi: 10.1128/iai.24.1.188-193.1979. [DOI] [PMC free article] [PubMed] [Google Scholar]
  60. Moss R. B., Hsu Y. P., Lewiston N. J., Curd J. G., Milgrom H., Hart S., Dyer B., Larrick J. W. Association of systemic immune complexes, complement activation, and antibodies to Pseudomonas aeruginosa lipopolysaccharide and exotoxin A with mortality in cystic fibrosis. Am Rev Respir Dis. 1986 Apr;133(4):648–652. doi: 10.1164/arrd.1986.133.4.648. [DOI] [PubMed] [Google Scholar]
  61. Mukhopadhyay S., Singh M., Cater J. I., Ogston S., Franklin M., Olver R. E. Nebulised antipseudomonal antibiotic therapy in cystic fibrosis: a meta-analysis of benefits and risks. Thorax. 1996 Apr;51(4):364–368. doi: 10.1136/thx.51.4.364. [DOI] [PMC free article] [PubMed] [Google Scholar]
  62. Mukhopadhyay S., Staddon G. E., Eastman C., Palmer M., Davies E. R., Carswell F. The quantitative distribution of nebulized antibiotic in the lung in cystic fibrosis. Respir Med. 1994 Mar;88(3):203–211. doi: 10.1016/s0954-6111(05)80348-8. [DOI] [PubMed] [Google Scholar]
  63. Nakamura H., Yoshimura K., McElvaney N. G., Crystal R. G. Neutrophil elastase in respiratory epithelial lining fluid of individuals with cystic fibrosis induces interleukin-8 gene expression in a human bronchial epithelial cell line. J Clin Invest. 1992 May;89(5):1478–1484. doi: 10.1172/JCI115738. [DOI] [PMC free article] [PubMed] [Google Scholar]
  64. Neu H. C. The role of Pseudomonas aeruginosa in infections. J Antimicrob Chemother. 1983 May;11 (Suppl B):1–13. doi: 10.1093/jac/11.suppl_b.1. [DOI] [PubMed] [Google Scholar]
  65. Ogle J. W., Janda J. M., Woods D. E., Vasil M. L. Characterization and use of a DNA probe as an epidemiological marker for Pseudomonas aeruginosa. J Infect Dis. 1987 Jan;155(1):119–126. doi: 10.1093/infdis/155.1.119. [DOI] [PubMed] [Google Scholar]
  66. Peckham D., Knox A. Intravenous antibiotic therapy in cystic fibrosis: in hospital or at home? Respir Med. 1993 Jul;87(5):329–330. doi: 10.1016/0954-6111(93)90045-2. [DOI] [PubMed] [Google Scholar]
  67. Pedersen S. S., Høiby N., Espersen F., Koch C. Role of alginate in infection with mucoid Pseudomonas aeruginosa in cystic fibrosis. Thorax. 1992 Jan;47(1):6–13. doi: 10.1136/thx.47.1.6. [DOI] [PMC free article] [PubMed] [Google Scholar]
  68. Pier G. B., Grout M., Zaidi T. S., Olsen J. C., Johnson L. G., Yankaskas J. R., Goldberg J. B. Role of mutant CFTR in hypersusceptibility of cystic fibrosis patients to lung infections. Science. 1996 Jan 5;271(5245):64–67. doi: 10.1126/science.271.5245.64. [DOI] [PMC free article] [PubMed] [Google Scholar]
  69. Pier G. B. Pulmonary disease associated with Pseudomonas aeruginosa in cystic fibrosis: current status of the host-bacterium interaction. J Infect Dis. 1985 Apr;151(4):575–580. doi: 10.1093/infdis/151.4.575. [DOI] [PubMed] [Google Scholar]
  70. Pitt T. L. Biology of Pseudomonas aeruginosa in relation to pulmonary infection in cystic fibrosis. J R Soc Med. 1986;79 (Suppl 12):13–18. [PMC free article] [PubMed] [Google Scholar]
  71. Plotkowski M. C., Chevillard M., Pierrot D., Altemayer D., Zahm J. M., Colliot G., Puchelle E. Differential adhesion of Pseudomonas aeruginosa to human respiratory epithelial cells in primary culture. J Clin Invest. 1991 Jun;87(6):2018–2028. doi: 10.1172/JCI115231. [DOI] [PMC free article] [PubMed] [Google Scholar]
  72. Prince A. Adhesins and receptors of Pseudomonas aeruginosa associated with infection of the respiratory tract. Microb Pathog. 1992 Oct;13(4):251–260. doi: 10.1016/0882-4010(92)90035-m. [DOI] [PubMed] [Google Scholar]
  73. Ramphal R., Carnoy C., Fievre S., Michalski J. C., Houdret N., Lamblin G., Strecker G., Roussel P. Pseudomonas aeruginosa recognizes carbohydrate chains containing type 1 (Gal beta 1-3GlcNAc) or type 2 (Gal beta 1-4GlcNAc) disaccharide units. Infect Immun. 1991 Feb;59(2):700–704. doi: 10.1128/iai.59.2.700-704.1991. [DOI] [PMC free article] [PubMed] [Google Scholar]
  74. Ramphal R., Pier G. B. Role of Pseudomonas aeruginosa mucoid exopolysaccharide in adherence to tracheal cells. Infect Immun. 1985 Jan;47(1):1–4. doi: 10.1128/iai.47.1.1-4.1985. [DOI] [PMC free article] [PubMed] [Google Scholar]
  75. Ramphal R., Sadoff J. C., Pyle M., Silipigni J. D. Role of pili in the adherence of Pseudomonas aeruginosa to injured tracheal epithelium. Infect Immun. 1984 Apr;44(1):38–40. doi: 10.1128/iai.44.1.38-40.1984. [DOI] [PMC free article] [PubMed] [Google Scholar]
  76. Ramsey B. W., Dorkin H. L., Eisenberg J. D., Gibson R. L., Harwood I. R., Kravitz R. M., Schidlow D. V., Wilmott R. W., Astley S. J., McBurnie M. A. Efficacy of aerosolized tobramycin in patients with cystic fibrosis. N Engl J Med. 1993 Jun 17;328(24):1740–1746. doi: 10.1056/NEJM199306173282403. [DOI] [PubMed] [Google Scholar]
  77. Ras G. J., Anderson R., Taylor G. W., Savage J. E., Van Niekerk E., Wilson R., Cole P. J. Proinflammatory interactions of pyocyanin and 1-hydroxyphenazine with human neutrophils in vitro. J Infect Dis. 1990 Jul;162(1):178–185. doi: 10.1093/infdis/162.1.178. [DOI] [PubMed] [Google Scholar]
  78. Rayner C. F., Tillotson G., Cole P. J., Wilson R. Efficacy and safety of long-term ciprofloxacin in the management of severe bronchiectasis. J Antimicrob Chemother. 1994 Jul;34(1):149–156. doi: 10.1093/jac/34.1.149. [DOI] [PubMed] [Google Scholar]
  79. Reddy M. S. Human tracheobronchial mucin: purification and binding to Pseudomonas aeruginosa. Infect Immun. 1992 Apr;60(4):1530–1535. doi: 10.1128/iai.60.4.1530-1535.1992. [DOI] [PMC free article] [PubMed] [Google Scholar]
  80. Rosenstein B. J., Eigen H. Risks of alternate-day prednisone in patients with cystic fibrosis. Pediatrics. 1991 Feb;87(2):245–246. [PubMed] [Google Scholar]
  81. Römling U., Fiedler B., Bosshammer J., Grothues D., Greipel J., von der Hardt H., Tümmler B. Epidemiology of chronic Pseudomonas aeruginosa infections in cystic fibrosis. J Infect Dis. 1994 Dec;170(6):1616–1621. doi: 10.1093/infdis/170.6.1616. [DOI] [PubMed] [Google Scholar]
  82. Saiman L., Cacalano G., Gruenert D., Prince A. Comparison of adherence of Pseudomonas aeruginosa to respiratory epithelial cells from cystic fibrosis patients and healthy subjects. Infect Immun. 1992 Jul;60(7):2808–2814. doi: 10.1128/iai.60.7.2808-2814.1992. [DOI] [PMC free article] [PubMed] [Google Scholar]
  83. Saiman L., Prince A. Pseudomonas aeruginosa pili bind to asialoGM1 which is increased on the surface of cystic fibrosis epithelial cells. J Clin Invest. 1993 Oct;92(4):1875–1880. doi: 10.1172/JCI116779. [DOI] [PMC free article] [PubMed] [Google Scholar]
  84. Sajjan U., Reisman J., Doig P., Irvin R. T., Forstner G., Forstner J. Binding of nonmucoid Pseudomonas aeruginosa to normal human intestinal mucin and respiratory mucin from patients with cystic fibrosis. J Clin Invest. 1992 Feb;89(2):657–665. doi: 10.1172/JCI115632. [DOI] [PMC free article] [PubMed] [Google Scholar]
  85. Schaad U. B., Wedgwood-Krucko J., Suter S., Kraemer R. Efficacy of inhaled amikacin as adjunct to intravenous combination therapy (ceftazidime and amikacin) in cystic fibrosis. J Pediatr. 1987 Oct;111(4):599–605. doi: 10.1016/s0022-3476(87)80130-0. [DOI] [PubMed] [Google Scholar]
  86. Schreiber J. R., Pier G. B., Grout M., Nixon K., Patawaran M. Induction of opsonic antibodies to Pseudomonas aeruginosa mucoid exopolysaccharide by an anti-idiotypic monoclonal antibody. J Infect Dis. 1991 Sep;164(3):507–514. doi: 10.1093/infdis/164.3.507. [DOI] [PubMed] [Google Scholar]
  87. Silva J. R., Jones J. A., Cole P. J., Poulter L. W. The immunological component of the cellular inflammatory infiltrate in bronchiectasis. Thorax. 1989 Aug;44(8):668–673. doi: 10.1136/thx.44.8.668. [DOI] [PMC free article] [PubMed] [Google Scholar]
  88. Simpson D. A., Ramphal R., Lory S. Characterization of Pseudomonas aeruginosa fliO, a gene involved in flagellar biosynthesis and adherence. Infect Immun. 1995 Aug;63(8):2950–2957. doi: 10.1128/iai.63.8.2950-2957.1995. [DOI] [PMC free article] [PubMed] [Google Scholar]
  89. Smith J. J., Travis S. M., Greenberg E. P., Welsh M. J. Cystic fibrosis airway epithelia fail to kill bacteria because of abnormal airway surface fluid. Cell. 1996 Apr 19;85(2):229–236. doi: 10.1016/s0092-8674(00)81099-5. [DOI] [PubMed] [Google Scholar]
  90. Somerville M., Richardson P. S., Rutman A., Wilson R., Cole P. J. Stimulation of secretion into human and feline airways by Pseudomonas aeruginosa proteases. J Appl Physiol (1985) 1991 May;70(5):2259–2267. doi: 10.1152/jappl.1991.70.5.2259. [DOI] [PubMed] [Google Scholar]
  91. Somerville M., Taylor G. W., Watson D., Rendell N. B., Rutman A., Todd H., Davies J. R., Wilson R., Cole P., Richardson P. S. Release of mucus glycoconjugates by Pseudomonas aeruginosa rhamnolipid into feline trachea in vivo and human bronchus in vitro. Am J Respir Cell Mol Biol. 1992 Jan;6(1):116–122. doi: 10.1165/ajrcmb/6.1.116. [DOI] [PubMed] [Google Scholar]
  92. Sommerhoff C. P., Nadel J. A., Basbaum C. B., Caughey G. H. Neutrophil elastase and cathepsin G stimulate secretion from cultured bovine airway gland serous cells. J Clin Invest. 1990 Mar;85(3):682–689. doi: 10.1172/JCI114492. [DOI] [PMC free article] [PubMed] [Google Scholar]
  93. Speert D. P., Campbell M. E., Farmer S. W., Volpel K., Joffe A. M., Paranchych W. Use of a pilin gene probe to study molecular epidemiology of Pseudomonas aeruginosa. J Clin Microbiol. 1989 Nov;27(11):2589–2593. doi: 10.1128/jcm.27.11.2589-2593.1989. [DOI] [PMC free article] [PubMed] [Google Scholar]
  94. Stableforth D. E., Smith D. L. Pseudomonas cepacia in cystic fibrosis. Thorax. 1994 Jul;49(7):629–630. doi: 10.1136/thx.49.7.629. [DOI] [PMC free article] [PubMed] [Google Scholar]
  95. Stead R. J., Hodson M. E., Batten J. C. Inhaled ceftazidime compared with gentamicin and carbenicillin in older patients with cystic fibrosis infected with Pseudomonas aeruginosa. Br J Dis Chest. 1987 Jul;81(3):272–279. doi: 10.1016/0007-0971(87)90161-6. [DOI] [PubMed] [Google Scholar]
  96. Steinbach S., Sun L., Jiang R. Z., Flume P., Gilligan P., Egan T. M., Goldstein R. Transmissibility of Pseudomonas cepacia infection in clinic patients and lung-transplant recipients with cystic fibrosis. N Engl J Med. 1994 Oct 13;331(15):981–987. doi: 10.1056/NEJM199410133311504. [DOI] [PubMed] [Google Scholar]
  97. Suter S. New perspectives in understanding and management of the respiratory disease in cystic fibrosis. Eur J Pediatr. 1994 Mar;153(3):144–150. doi: 10.1007/BF01958972. [DOI] [PubMed] [Google Scholar]
  98. Suter S., Schaad U. B., Tegner H., Ohlsson K., Desgrandchamps D., Waldvogel F. A. Levels of free granulocyte elastase in bronchial secretions from patients with cystic fibrosis: effect of antimicrobial treatment against Pseudomonas aeruginosa. J Infect Dis. 1986 May;153(5):902–909. doi: 10.1093/infdis/153.5.902. [DOI] [PubMed] [Google Scholar]
  99. Szaff M., Høiby N., Flensborg E. W. Frequent antibiotic therapy improves survival of cystic fibrosis patients with chronic Pseudomonas aeruginosa infection. Acta Paediatr Scand. 1983 Sep;72(5):651–657. doi: 10.1111/j.1651-2227.1983.tb09789.x. [DOI] [PubMed] [Google Scholar]
  100. Tablan O. C., Chorba T. L., Schidlow D. V., White J. W., Hardy K. A., Gilligan P. H., Morgan W. M., Carson L. A., Martone W. J., Jason J. M. Pseudomonas cepacia colonization in patients with cystic fibrosis: risk factors and clinical outcome. J Pediatr. 1985 Sep;107(3):382–387. doi: 10.1016/s0022-3476(85)80511-4. [DOI] [PubMed] [Google Scholar]
  101. Tanaka E., Kanthakumar K., Cundell D. R., Tsang K. W., Taylor G. W., Kuze F., Cole P. J., Wilson R. The effect of erythromycin on Pseudomonas aeruginosa and neutrophil mediated epithelial damage. J Antimicrob Chemother. 1994 Apr;33(4):765–775. doi: 10.1093/jac/33.4.765. [DOI] [PubMed] [Google Scholar]
  102. Taylor R. F., Gaya H., Hodson M. E. Pseudomonas cepacia: pulmonary infection in patients with cystic fibrosis. Respir Med. 1993 Apr;87(3):187–192. doi: 10.1016/0954-6111(93)90090-m. [DOI] [PubMed] [Google Scholar]
  103. Tosi M. F., Zakem H., Berger M. Neutrophil elastase cleaves C3bi on opsonized pseudomonas as well as CR1 on neutrophils to create a functionally important opsonin receptor mismatch. J Clin Invest. 1990 Jul;86(1):300–308. doi: 10.1172/JCI114699. [DOI] [PMC free article] [PubMed] [Google Scholar]
  104. Tsang K. W., Rutman A., Tanaka E., Lund V., Dewar A., Cole P. J., Wilson R. Interaction of Pseudomonas aeruginosa with human respiratory mucosa in vitro. Eur Respir J. 1994 Oct;7(10):1746–1753. doi: 10.1183/09031936.94.07101746. [DOI] [PubMed] [Google Scholar]
  105. Tümmler B., Koopmann U., Grothues D., Weissbrodt H., Steinkamp G., von der Hardt H. Nosocomial acquisition of Pseudomonas aeruginosa by cystic fibrosis patients. J Clin Microbiol. 1991 Jun;29(6):1265–1267. doi: 10.1128/jcm.29.6.1265-1267.1991. [DOI] [PMC free article] [PubMed] [Google Scholar]
  106. Valerius N. H., Koch C., Høiby N. Prevention of chronic Pseudomonas aeruginosa colonisation in cystic fibrosis by early treatment. Lancet. 1991 Sep 21;338(8769):725–726. doi: 10.1016/0140-6736(91)91446-2. [DOI] [PubMed] [Google Scholar]
  107. Vishwanath S., Ramphal R. Adherence of Pseudomonas aeruginosa to human tracheobronchial mucin. Infect Immun. 1984 Jul;45(1):197–202. doi: 10.1128/iai.45.1.197-202.1984. [DOI] [PMC free article] [PubMed] [Google Scholar]
  108. Vishwanath S., Ramphal R. Tracheobronchial mucin receptor for Pseudomonas aeruginosa: predominance of amino sugars in binding sites. Infect Immun. 1985 May;48(2):331–335. doi: 10.1128/iai.48.2.331-335.1985. [DOI] [PMC free article] [PubMed] [Google Scholar]
  109. Vogelmeier C., Hubbard R. C., Fells G. A., Schnebli H. P., Thompson R. C., Fritz H., Crystal R. G. Anti-neutrophil elastase defense of the normal human respiratory epithelial surface provided by the secretory leukoprotease inhibitor. J Clin Invest. 1991 Feb;87(2):482–488. doi: 10.1172/JCI115021. [DOI] [PMC free article] [PubMed] [Google Scholar]
  110. Wilson C. B., Jones P. W., O'Leary C. J., Hansell D. M., Cole P. J., Wilson R. Effect of sputum bacteriology on the quality of life of patients with bronchiectasis. Eur Respir J. 1997 Aug;10(8):1754–1760. doi: 10.1183/09031936.97.10081754. [DOI] [PubMed] [Google Scholar]
  111. Wilson R., Pitt T., Taylor G., Watson D., MacDermot J., Sykes D., Roberts D., Cole P. Pyocyanin and 1-hydroxyphenazine produced by Pseudomonas aeruginosa inhibit the beating of human respiratory cilia in vitro. J Clin Invest. 1987 Jan;79(1):221–229. doi: 10.1172/JCI112787. [DOI] [PMC free article] [PubMed] [Google Scholar]
  112. Winnie G. B., Cowan R. G. Respiratory tract colonization with Pseudomonas aeruginosa in cystic fibrosis: correlations between anti-Pseudomonas aeruginosa antibody levels and pulmonary function. Pediatr Pulmonol. 1991;10(2):92–100. doi: 10.1002/ppul.1950100210. [DOI] [PubMed] [Google Scholar]
  113. Woods D. E., Straus D. C., Johanson W. G., Jr, Berry V. K., Bass J. A. Role of pili in adherence of Pseudomonas aeruginosa to mammalian buccal epithelial cells. Infect Immun. 1980 Sep;29(3):1146–1151. doi: 10.1128/iai.29.3.1146-1151.1980. [DOI] [PMC free article] [PubMed] [Google Scholar]
  114. Yeates D. B., Sturgess J. M., Kahn S. R., Levison H., Aspin N. Mucociliary transport in trachea of patients with cystic fibrosis. Arch Dis Child. 1976 Jan;51(1):28–33. doi: 10.1136/adc.51.1.28. [DOI] [PMC free article] [PubMed] [Google Scholar]
  115. Zar H., Saiman L., Quittell L., Prince A. Binding of Pseudomonas aeruginosa to respiratory epithelial cells from patients with various mutations in the cystic fibrosis transmembrane regulator. J Pediatr. 1995 Feb;126(2):230–233. doi: 10.1016/s0022-3476(95)70549-x. [DOI] [PubMed] [Google Scholar]
  116. de Bentzmann S., Plotkowski C., Puchelle E. Receptors in the Pseudomonas aeruginosa adherence to injured and repairing airway epithelium. Am J Respir Crit Care Med. 1996 Oct;154(4 Pt 2):S155–S162. doi: 10.1164/ajrccm/154.4_Pt_2.S155. [DOI] [PubMed] [Google Scholar]

Articles from Thorax are provided here courtesy of BMJ Publishing Group

RESOURCES